Asia Pacific Neutropenia Treatment Market By Distribution channel (Retail pharmacies, Hospital pharmacies and Online pharmacies), By Treatment (Colony-stimulating factor, Antibiotics, Antifungals and Antivirals), By Country, Industry Analysis and Forecast, 2020 - 2026
The Asia Pacific Neutropenia Treatment Market would witness market growth of 7.6% CAGR during the forecast period (2020-2026).
Neutropenia itself has no specific symptoms but is usually treated with a fever or infection. Often, persistent infection is also what leads doctors to test blood cell counts to identify blood cell cancers such as leukemia. Severe infections can develop quickly when a patient is neutropenic and become overwhelming within minutes to hours. Fortunately, since doctors expect potential changes in immune responses during multiple cancer treatments, they pay careful attention to variations in blood counts to avoid these events.
Cytotoxic chemotherapy can cause severe and often prolonged neutropenia, which can lead to Retailization for fever care or possibly fatal infection. While deep sustained neutropenia is more likely to occur in the pre-engraft process of hematopoietic cell transplantation and in patients undergoing acute leukemia induction therapy, chemotherapy-related neutropenia that also occurs in patients undergoing standard-dose chemotherapy for certain neoplasms. To eliminate infectious risks, recombinant human granulocyte stimulating factor (G-CSF; filgrastim and pegylated filgrastim) and granulocyte-macrophage stimulating factor (GM-CSF; sargramostim) have been used to decrease the length and degree of neutropenia.
A rise in the prevalence of leukemia, an increase in R&D activities and the production of new drugs, and a paradigm change from branded drugs to biosimilars in cancer-friendly treatment, are transforming the global neutropenia treatment industry. Nevertheless, high costs for the diagnosis of neutropenia and stringent rules for the clearance of products hinder the growth of the market. On the contrary, the robust neutropenia drug pipeline will open up new opportunities for market players over the coming years.
Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.
Scope of the Study
Market Segmentation:
By Distribution Channel
Neutropenia itself has no specific symptoms but is usually treated with a fever or infection. Often, persistent infection is also what leads doctors to test blood cell counts to identify blood cell cancers such as leukemia. Severe infections can develop quickly when a patient is neutropenic and become overwhelming within minutes to hours. Fortunately, since doctors expect potential changes in immune responses during multiple cancer treatments, they pay careful attention to variations in blood counts to avoid these events.
Cytotoxic chemotherapy can cause severe and often prolonged neutropenia, which can lead to Retailization for fever care or possibly fatal infection. While deep sustained neutropenia is more likely to occur in the pre-engraft process of hematopoietic cell transplantation and in patients undergoing acute leukemia induction therapy, chemotherapy-related neutropenia that also occurs in patients undergoing standard-dose chemotherapy for certain neoplasms. To eliminate infectious risks, recombinant human granulocyte stimulating factor (G-CSF; filgrastim and pegylated filgrastim) and granulocyte-macrophage stimulating factor (GM-CSF; sargramostim) have been used to decrease the length and degree of neutropenia.
A rise in the prevalence of leukemia, an increase in R&D activities and the production of new drugs, and a paradigm change from branded drugs to biosimilars in cancer-friendly treatment, are transforming the global neutropenia treatment industry. Nevertheless, high costs for the diagnosis of neutropenia and stringent rules for the clearance of products hinder the growth of the market. On the contrary, the robust neutropenia drug pipeline will open up new opportunities for market players over the coming years.
Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.
Scope of the Study
Market Segmentation:
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies and
- Online pharmacies
- Colony-stimulating factor
- Antibiotics
- Antifungals and
- Antivirals
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- Amgen, Inc.
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- BeyondSpring, Inc.
- Spectrum Pharmaceuticals, Inc.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Mylan N.V.
- Cellerant Therapeutics, Inc.
- Partner Therapeutics, Inc.
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Neutropenia Treatment Market, by Distribution Channel
1.4.2 Asia Pacific Neutropenia Treatment Market, by Treatment
1.4.3 Asia Pacific Neutropenia Treatment Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL
3.1 Asia Pacific Retail pharmacies Market by Country
3.2 Asia Pacific Hospital pharmacies Market by Country
3.3 Asia Pacific Online pharmacies Market by Country
CHAPTER 4. ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT
4.1 Asia Pacific Colony-stimulating factor Market by Country
4.2 Asia Pacific Antibiotics Market by Country
4.3 Asia Pacific Antifungals Market by Country
4.4 Asia Pacific Antivirals Market by Country
CHAPTER 5. ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY COUNTRY
5.1 China Neutropenia Treatment Market
5.1.1 China Neutropenia Treatment Market by Distribution channel
5.1.2 China Neutropenia Treatment Market by Treatment
5.2 Japan Neutropenia Treatment Market
5.2.1 Japan Neutropenia Treatment Market by Distribution channel
5.2.2 Japan Neutropenia Treatment Market by Treatment
5.3 India Neutropenia Treatment Market
5.3.1 India Neutropenia Treatment Market by Distribution channel
5.3.2 India Neutropenia Treatment Market by Treatment
5.4 South Korea Neutropenia Treatment Market
5.4.1 South Korea Neutropenia Treatment Market by Distribution channel
5.4.2 South Korea Neutropenia Treatment Market by Treatment
5.5 Singapore Neutropenia Treatment Market
5.5.1 Singapore Neutropenia Treatment Market by Distribution channel
5.5.2 Singapore Neutropenia Treatment Market by Treatment
5.6 Malaysia Neutropenia Treatment Market
5.6.1 Malaysia Neutropenia Treatment Market by Distribution channel
5.6.2 Malaysia Neutropenia Treatment Market by Treatment
5.7 Rest of Asia Pacific Neutropenia Treatment Market
5.7.1 Rest of Asia Pacific Neutropenia Treatment Market by Distribution channel
5.7.2 Rest of Asia Pacific Neutropenia Treatment Market by Treatment
CHAPTER 6. COMPANY PROFILES
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.2 Novartis AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.3.4.2 Acquisition and Mergers:
6.4 Teva Pharmaceutical Industries Ltd.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 BeyondSpring, Inc.
6.5.1 Company Overview
6.6 Spectrum Pharmaceuticals, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Kyowa Kirin Co., Ltd. (Kirin Company)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Mylan N.V.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.9 Cellerant Therapeuticsc, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Approvals:
6.1 Partner Therapeutics, Inc.
6.10.1 Company overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Approvals:
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Neutropenia Treatment Market, by Distribution Channel
1.4.2 Asia Pacific Neutropenia Treatment Market, by Treatment
1.4.3 Asia Pacific Neutropenia Treatment Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL
3.1 Asia Pacific Retail pharmacies Market by Country
3.2 Asia Pacific Hospital pharmacies Market by Country
3.3 Asia Pacific Online pharmacies Market by Country
CHAPTER 4. ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT
4.1 Asia Pacific Colony-stimulating factor Market by Country
4.2 Asia Pacific Antibiotics Market by Country
4.3 Asia Pacific Antifungals Market by Country
4.4 Asia Pacific Antivirals Market by Country
CHAPTER 5. ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY COUNTRY
5.1 China Neutropenia Treatment Market
5.1.1 China Neutropenia Treatment Market by Distribution channel
5.1.2 China Neutropenia Treatment Market by Treatment
5.2 Japan Neutropenia Treatment Market
5.2.1 Japan Neutropenia Treatment Market by Distribution channel
5.2.2 Japan Neutropenia Treatment Market by Treatment
5.3 India Neutropenia Treatment Market
5.3.1 India Neutropenia Treatment Market by Distribution channel
5.3.2 India Neutropenia Treatment Market by Treatment
5.4 South Korea Neutropenia Treatment Market
5.4.1 South Korea Neutropenia Treatment Market by Distribution channel
5.4.2 South Korea Neutropenia Treatment Market by Treatment
5.5 Singapore Neutropenia Treatment Market
5.5.1 Singapore Neutropenia Treatment Market by Distribution channel
5.5.2 Singapore Neutropenia Treatment Market by Treatment
5.6 Malaysia Neutropenia Treatment Market
5.6.1 Malaysia Neutropenia Treatment Market by Distribution channel
5.6.2 Malaysia Neutropenia Treatment Market by Treatment
5.7 Rest of Asia Pacific Neutropenia Treatment Market
5.7.1 Rest of Asia Pacific Neutropenia Treatment Market by Distribution channel
5.7.2 Rest of Asia Pacific Neutropenia Treatment Market by Treatment
CHAPTER 6. COMPANY PROFILES
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.2 Novartis AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.3.4.2 Acquisition and Mergers:
6.4 Teva Pharmaceutical Industries Ltd.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 BeyondSpring, Inc.
6.5.1 Company Overview
6.6 Spectrum Pharmaceuticals, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Kyowa Kirin Co., Ltd. (Kirin Company)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Mylan N.V.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.9 Cellerant Therapeuticsc, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Approvals:
6.1 Partner Therapeutics, Inc.
6.10.1 Company overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Approvals:
LIST OF TABLES
TABLE 1 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 2 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 3 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 4 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 5 ASIA PACIFIC RETAIL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 ASIA PACIFIC RETAIL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 ASIA PACIFIC HOSPITAL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 ASIA PACIFIC HOSPITAL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 ASIA PACIFIC ONLINE PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 ASIA PACIFIC ONLINE PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 12 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 13 ASIA PACIFIC COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 ASIA PACIFIC COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 ASIA PACIFIC ANTIBIOTICS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 ASIA PACIFIC ANTIBIOTICS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 ASIA PACIFIC ANTIFUNGALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 ASIA PACIFIC ANTIFUNGALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 ASIA PACIFIC ANTIVIRALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 ASIA PACIFIC ANTIVIRALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 CHINA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 24 CHINA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 25 CHINA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 26 CHINA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 27 CHINA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 28 CHINA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 29 JAPAN NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 30 JAPAN NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 31 JAPAN NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 32 JAPAN NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 33 JAPAN NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 34 JAPAN NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 35 INDIA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 36 INDIA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 37 INDIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 38 INDIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 39 INDIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 40 INDIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 41 SOUTH KOREA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 42 SOUTH KOREA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 43 SOUTH KOREA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 44 SOUTH KOREA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 45 SOUTH KOREA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 46 SOUTH KOREA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 47 SINGAPORE NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 48 SINGAPORE NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 49 SINGAPORE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 50 SINGAPORE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 51 SINGAPORE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 52 SINGAPORE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 53 MALAYSIA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 54 MALAYSIA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 55 MALAYSIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 56 MALAYSIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 57 MALAYSIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 58 MALAYSIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 59 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 60 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 61 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 62 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 63 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 64 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 65 KEY INFORMATION – AMGEN, INC.
TABLE 66 KEY INFORMATION – NOVARTIS AG
TABLE 67 KEY INFORMATION – PFIZER, INC.
TABLE 68 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 69 KEY INFORMATION – BEYONDSPRING, INC.
TABLE 70 KEY INFORMATION – SPECTRUM PHARMACEUTICALS, INC.
TABLE 71 KEY INFORMATION – KYOWA KIRIN CO., LTD.
TABLE 72 KEY INFORMATION – MYLAN N.V.
TABLE 73 KEY INFORMATION – CELLERANT THERAPEUTICS, INC.
TABLE 74 KEY INFORMATION – PARTNER THERAPEUTICS, INC.
TABLE 1 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 2 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 3 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 4 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 5 ASIA PACIFIC RETAIL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 ASIA PACIFIC RETAIL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 ASIA PACIFIC HOSPITAL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 ASIA PACIFIC HOSPITAL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 ASIA PACIFIC ONLINE PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 ASIA PACIFIC ONLINE PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 12 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 13 ASIA PACIFIC COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 ASIA PACIFIC COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 ASIA PACIFIC ANTIBIOTICS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 ASIA PACIFIC ANTIBIOTICS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 ASIA PACIFIC ANTIFUNGALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 ASIA PACIFIC ANTIFUNGALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 ASIA PACIFIC ANTIVIRALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 ASIA PACIFIC ANTIVIRALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 CHINA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 24 CHINA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 25 CHINA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 26 CHINA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 27 CHINA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 28 CHINA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 29 JAPAN NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 30 JAPAN NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 31 JAPAN NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 32 JAPAN NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 33 JAPAN NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 34 JAPAN NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 35 INDIA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 36 INDIA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 37 INDIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 38 INDIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 39 INDIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 40 INDIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 41 SOUTH KOREA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 42 SOUTH KOREA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 43 SOUTH KOREA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 44 SOUTH KOREA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 45 SOUTH KOREA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 46 SOUTH KOREA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 47 SINGAPORE NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 48 SINGAPORE NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 49 SINGAPORE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 50 SINGAPORE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 51 SINGAPORE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 52 SINGAPORE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 53 MALAYSIA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 54 MALAYSIA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 55 MALAYSIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 56 MALAYSIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 57 MALAYSIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 58 MALAYSIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 59 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 60 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 61 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 62 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 63 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 64 REST OF ASIA PACIFIC NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 65 KEY INFORMATION – AMGEN, INC.
TABLE 66 KEY INFORMATION – NOVARTIS AG
TABLE 67 KEY INFORMATION – PFIZER, INC.
TABLE 68 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 69 KEY INFORMATION – BEYONDSPRING, INC.
TABLE 70 KEY INFORMATION – SPECTRUM PHARMACEUTICALS, INC.
TABLE 71 KEY INFORMATION – KYOWA KIRIN CO., LTD.
TABLE 72 KEY INFORMATION – MYLAN N.V.
TABLE 73 KEY INFORMATION – CELLERANT THERAPEUTICS, INC.
TABLE 74 KEY INFORMATION – PARTNER THERAPEUTICS, INC.
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 1 METHODOLOGY FOR THE RESEARCH
